Search results
Results from the WOW.Com Content Network
As of 2023, the Indian pharmaceutical industry is the world's 13th largest by value and third largest in the world by volume. [8] The industry produces over 60,000 generic drugs in different 60 therapeutic categories. [8] India's revenue from pharmaceutical exports was $25.3 billion in the 2022-2023 financial year. [7]
Gujarat accounts for a minimum of 28% of India's pharma exports, with exports totalling $5.36bn in 2018–19, up from $4.83bn the previous year. The Indian pharma industry has bounced back with an estimated export value of $19.15bn in 2018–19, an increase of 10.85% over the previous year.
The Indian government has announced its plan to bring all medical devices, including implants and contraceptives under a review of the Central Drugs and Standard Control Organisation (CDSCO). Within the CDSCO, the Drug Controller General of India (DCGI) regulates pharmaceutical and medical devices and is positioning within the Ministry of ...
The company's first international move took it to Russia in 1992. There, Dr. Reddy's formed a joint venture with the country's biggest pharmaceuticals producer, Biomed.They pulled out in 1995 amid accusations of scandal, involving "a significant material loss due to the activities of Moscow's branch of Reddy's Labs with the help of Biomed's chief executive". [8]
"Drugs and Cosmetics Rules, 1945" (PDF). Central Drugs Standard Control Organization.Archived from the original (PDF) on 31 October 2005.; A Review on the Current Classification and Regulatory Provisions for Medicines in Drug & Cosmetic Act, in the light of Present Day Context Recommendations for Drugs & Cosmetics Rules with context of Drug Schedules
The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. [20] India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports.
The Truth Pill: The Myth of Drug Regulation in India is a 2022 book by whistleblower Dinesh Thakur and lawyer Prashant Reddy. The book highlights the problems in India's drug regulatory framework, and the government oversight relating to poor manufacturing practices and clinical trials of drugs by Indian pharmaceutical companies.
Alembic Pharmaceuticals; Aston Sequoia; Cadila Pharmaceuticals; Century Pharmaceuticals; Deepak Nitrite; Dishman Carbogen Amcis; Indian Petrochemicals Corporation Limited; Intas Pharmaceuticals; National Institute of Pharmaceutical Education and Research, Ahmedabad; Pharmaceutical industry in Gujarat; Pharmaceutical industry in India; Zydus ...